Daré Bioscience, Inc. (DARE) DCF Valuation

Daré Bioscience, Inc. (Dare) DCF Valoración

US | Healthcare | Biotechnology | NASDAQ
Daré Bioscience, Inc. (DARE) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Daré Bioscience, Inc. (DARE) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¿Busca evaluar el valor intrínseco de Daré Bioscience, Inc.? Nuestra calculadora DARE DCF integra datos del mundo real con características integrales de personalización, lo que le permite refinar sus pronósticos y mejorar sus opciones de inversión.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 10.0 2.8 2.3 1.9 1.5 1.3 1.0
Revenue Growth, % 0 0 0 0 -71.92 -17.98 -17.98 -17.98 -17.98 -17.98
EBITDA -14.3 -27.4 -39.0 -31.4 -30.9 .5 .4 .3 .3 .2
EBITDA, % 100 100 100 -313.61 -1100.53 20 20 20 20 20
Depreciation .0 .0 .0 .0 .0 1.4 1.1 .9 .8 .6
Depreciation, % 100 100 100 0.47617 1.37 60.37 60.37 60.37 60.37 60.37
EBIT -14.3 -27.4 -39.1 -31.4 -30.9 .5 .4 .3 .3 .2
EBIT, % 100 100 100 -314.09 -1101.89 20 20 20 20 20
Total Cash 4.8 4.7 51.7 34.7 10.5 2.3 1.9 1.5 1.3 1.0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .6 .5 1.1 1.7 .9
Account Receivables, % 100 100 100 17.03 33.81
Inventories -1,107.5 -1,852.4 -2,474.1 .0 .0 1.4 1.1 .9 .8 .6
Inventories, % 100 100 100 0 0 60 60 60 60 60
Accounts Payable 1.1 1.0 2.1 2.0 3.4 1.9 1.6 1.3 1.1 .9
Accounts Payable, % 100 100 100 20.28 120.57 84.06 84.06 84.06 84.06 84.06
Capital Expenditure .0 .0 .0 -.1 -.6 -.1 -.1 -.1 -.1 .0
Capital Expenditure, % 100 100 100 -0.63069 -22.42 -4.61 -4.61 -4.61 -4.61 -4.61
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -14.3 -27.4 -38.7 -31.4 -30.9 .5 .4 .3 .3 .2
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 1,093.7 717.6 583.4 -2,506.2 -29.4 -1.8 1.6 1.3 1.1 .9
WACC, % 10.42 10.42 10.42 10.42 10.42 10.42 10.42 10.42 10.42 10.42
PV UFCF
SUM PV UFCF 2.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 1
Terminal Value 11
Present Terminal Value 7
Enterprise Value 9
Net Debt -9
Equity Value 18
Diluted Shares Outstanding, MM 7
Equity Value Per Share 2.43

What You Will Get

  • Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: Daré Bioscience, Inc. (DARE) financial data pre-filled to facilitate your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically for you.
  • Customizable and Professional: A refined Excel model tailored to meet your valuation requirements.
  • Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.

Key Features

  • Comprehensive DARE Data: Pre-loaded with Daré Bioscience’s historical financials and future growth projections.
  • Customizable Assumptions: Modify revenue growth rates, profit margins, discount rates, tax implications, and capital investments.
  • Interactive Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on user-defined inputs.
  • Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
  • Intuitive Interface: Designed for ease of use, catering to both industry professionals and newcomers.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review Daré Bioscience’s pre-filled financial data and forecasts.
  3. Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Watch the DCF model update instantly as you tweak assumptions.
  5. Step 5: Analyze the outputs and use the results for investment decisions related to Daré Bioscience, Inc. (DARE).

Why Choose Daré Bioscience, Inc. (DARE)?

  • Innovative Solutions: Pioneering advancements in women's health and reproductive medicine.
  • Expert Team: Led by industry veterans with extensive experience in biopharmaceuticals.
  • Strong Pipeline: A robust portfolio of product candidates addressing unmet medical needs.
  • Commitment to Safety: Rigorous clinical trials ensure the highest standards of patient care.
  • Proven Track Record: Consistent progress and transparency in research and development efforts.

Who Should Use This Product?

  • Investors: Evaluate Daré Bioscience's (DARE) market potential before making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts.
  • Startup Founders: Understand how biotech companies like Daré Bioscience are valued in the market.
  • Consultants: Provide comprehensive valuation reports to clients in the life sciences sector.
  • Students and Educators: Utilize real-time data to learn and teach valuation strategies in biotechnology.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Daré Bioscience historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Daré Bioscience, Inc. (DARE).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.